Table 1.
Characteristics of ICI recipients and patients admitted for IrAE
| Characteristic | ICI recipients a | Patients admitted for IrAE b | IrAE admission rates c |
|---|---|---|---|
| Total ICI recipients | 2,884 | 344 (11.9) | |
| Age, mean (SD), years | 65.1 (13.2) | 64.5 (13.1) | |
| Female sex | 1,220 | 132 (38.3) | |
| Cancer type | |||
| Melanoma | 994 | 165 (48.0) | 16.6 |
| Thoracic | 776 | 77 (22.4) | 9.9 |
| Gastrointestinal | 354 | 43 (12.5) | 12.2 |
| Head and neck | 226 | 7 (2.0) | 3.1 |
| Genitourinary | 164 | 17 (4.9) | 10.4 |
| Gynecologic | 122 | 9 (2.6) | 7.4 |
| Hematologic | 89 | 10 (2.9) | 11.2 |
| Neurologic | 82 | 8 (2.3) | 9.8 |
| Breast | 60 | 7 (2.0) | 11.7 |
| Sarcoma | 17 | 1 (0.93) | 5.9 |
| ICI type | |||
| PD‐1/PD‐L1 | 2,265 | 223 (67.7) | 9.9 |
| CTLA4 | 355 | 67 (19.5) | 18.9 |
| CTLA4 + PD1 | 264 | 54 (15.7) | 20.5 |
a
Total number of ICI recipients for corresponding characteristic, unless otherwise indicated.
b
Data are presented as number (percentage) of patients admitted for irAE (excluding readmissions) unless otherwise indicated.
c
Data are presented as percentage of patients admitted for irAE within each row category (cancer and ICI type).
Abbreviations: CI, confidence interval; CTLA‐4, cytotoxic T‐lymphocyte antigen‐4; ICI, immune checkpoint inhibitor; irAE, immune‐related adverse event; OR, odds ratio; PD‐1, programmed death‐1; PD‐L1, programmed death‐ligand 1; SD, standard deviation.